These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. CD40 antibody as an adjuvant induces enhanced T cell responses. Carlring J; Barr TA; McCormick AL; Heath AW Vaccine; 2004 Sep; 22(25-26):3323-8. PubMed ID: 15308355 [TBL] [Abstract][Full Text] [Related]
7. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Hamdy S; Haddadi A; Hung RW; Lavasanifar A Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733 [TBL] [Abstract][Full Text] [Related]
8. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Morera Y; Bequet-Romero M; Ayala M; Pérez PP; Castro J; Sánchez J; Alba JS; Ancízar J; Cosme K; Gavilondo JV Vaccine; 2012 Jan; 30(2):368-77. PubMed ID: 22075086 [TBL] [Abstract][Full Text] [Related]
9. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Karbach J; Neumann A; Atmaca A; Wahle C; Brand K; von Boehmer L; Knuth A; Bender A; Ritter G; Old LJ; Jäger E Clin Cancer Res; 2011 Feb; 17(4):861-70. PubMed ID: 21163871 [TBL] [Abstract][Full Text] [Related]
13. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation. Schlom J; Palena C; Greiner JW; Tsang KY; Grosenbach DW; Sabzevari H; Gulley JL; Arlen PM; Kass E; Hodge JW Dev Biol (Basel); 2004; 116():27-47. PubMed ID: 15603182 [No Abstract] [Full Text] [Related]
15. Adjuvanticity of anti-cD40 in vaccine development. Cairing J; Barr T; Heath AW Curr Opin Mol Ther; 2005 Feb; 7(1):73-7. PubMed ID: 15732532 [TBL] [Abstract][Full Text] [Related]
16. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104 [TBL] [Abstract][Full Text] [Related]
17. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine. Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201 [TBL] [Abstract][Full Text] [Related]
18. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens. Barr TA; Carlring J; Heath AW Vaccine; 2005 May; 23(26):3477-82. PubMed ID: 15837371 [TBL] [Abstract][Full Text] [Related]
19. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses. Romeu B; Lastre M; Reyes L; González E; Borrero Y; Lescaille D; Pérez R; Nuñez D; Pérez O Vaccine; 2014 Dec; 32(51):6971-6978. PubMed ID: 25454865 [TBL] [Abstract][Full Text] [Related]
20. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens? Romeu B; Gonzalez E; Lastre M; Pérez O J Drug Target; 2012 Jul; 20(6):502-8. PubMed ID: 22632258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]